Sight Sciences Third Quarter 2026 Earnings Results - SIGHT SCIENCES INC

Explicit Guidance:

• Full-Year 2026 Revenue: Raised to $92–$93 million (previously $88–$92 million), representing ~20% full-year growth.
• Segment Revenue (FY 2026):
  • IDE (Interventional Dry Eye): Increased to ~$12 million (previously $9–$11 million).
  • IG (Interventional Glaucoma): Increased to $80–$81 million (previously $79–$81 million).
• Adjusted Operating Expenses (FY 2026): Maintained at $92–$94 million, representing 5–7% growth vs. prior year.
• 2027 Outlook: Management expressed confidence in maintaining "high growth" (>20% implied momentum) into 2027, driven by IG fundamentals and IDE scaling, though no specific numerical guidance for 2027 was provided.

Business-Segment Outlook:

• IDE (Tear Care):
  • Growth Trajectory: Anticipates rapid scaling as market access expands; current record growth driven by ordering accounts (222) and utilization (21 procedures/account).
  • Utilization: Significant room for growth expected as new accounts mature and the business expands beyond current limited reimbursed footprint.
  • Account Strategy: Focusing on collaborative care practices with high dry-eye volume; transitioning from cash-pay to reimbursed procedural models.
• IG (Glaucoma):
  • Product Launch: Full commercial launch of OmniUltra (next-generation technology) began in October following limited rollout; expected to support sustained growth and deepen customer engagement in 2027.
  • Workflow Activation: Continued focus on converting "standalone" opportunities into repeatable workflows for practices, moving beyond cataract-combo cases.
  • Market Share: Aiming to capture a larger share of combo cataract cases and activate standalone markets through practice-level workflow integration.
• Intersection of Intervention (IX): Expecting synergistic growth as IG relationships accelerate Tear Care adoption; anticipating shared patient pathways and commercial leverage between Omni and Tear Care.

Market and Competitive Outlook:

• Market Access (IDE): Anticipates payers (MACs and commercial) will establish fee schedules and coverage policies in the coming quarters; expects expansion of reimbursed procedural access to be a primary growth accelerator.
• Coverage Expansion: Celebrated Aetna's expansion of Omni and Scion coverage adding ~25 million covered lives; continuing dialogue with payers to replicate this success.
• Category Leadership: Believes the "interventional" paradigm is becoming a household term in ophthalmology; positions Sight Sciences as the unique provider of two reimbursed/interventional technologies addressing underlying causes of disease (glaucoma and MGD).
• Utilization Trends: Projected to increase significantly as the market matures from early adopters to broader practice integration; currently seeing higher quality/durability with collaborative care practices vs. historical cash-pay optometry models.

Macro / Industry Outlook:

• Treatment Paradigm: Management views the broader ophthalmic industry as shifting toward earlier, procedure-based care; believes intervening earlier is clinically superior for long-term patient outcomes.
• Payer Dynamics: Anticipates payers will favor treatments addressing underlying causes (e.g., meibomian gland function) over symptom management (drops), driving support for procedural interventions.
• Economic/Capital: Expecting to achieve cash flow break-even without raising additional equity; maintaining fiscal discipline while investing in growth.
• Debt Management: Extended interest-only period on $40 million debt to August 2027, providing capital flexibility to fund growth investments prior to principal amortization.

Strategic Initiatives:

• Product Innovation: Commercial launch of OmniUltra (US, October) featuring single-pass canaloplasty, TrueSync Plus, and improved visualization.
• Label Expansion: FDA label expansion for Tear Care now indicates improvement of meibomian gland function (first/only MGD treatment with this indication); leveraging this for payer education and marketing.
• Go-to-Market Expansion: Increasing sales and clinic support capacity to help practices establish workflows and patient flow; targeting regions with existing market access while expanding coverage policies.
• IX Platform Development: Building a scalable platform leveraging shared customers/patients between IG and IDE; activating cross-selling opportunities in practices managing both conditions.

Risks and Headwinds to Outlook:

• Market Access Timing: Revenue scaling depends on the speed of payer fee schedule establishment and coverage policy decisions; exact timing cannot be predicted.
• Early Stage Execution: IDE guidance includes conservatism due to the early market development stage; utilization rates vary widely among new accounts still building workflows.
• Reimbursement Dependency: Growth for IDE is currently concentrated in regions with existing reimbursement; expansion relies on overcoming payer resistance for new procedural interventions.
• Seasonality/Quarters: Guidance implies potential sequential deceleration in Q4 relative to Q3 peaks (specifically for IDE) due to seasonality and the need to set appropriate bars in an early-stage market.

Management Tone on the Future:

• Confidence Level: High confidence in the growth trajectory, citing "sustained growth," "record active accounts," and "operating leverage."
• Strategic Clarity: Management emphasizes a shift from "clinical education" to "commercial execution" and "activation," viewing the business as transitioning into a scalable, profitable phase.
• Differentiation: Strong conviction in the "Intersection of Intervention" (IX) as a durable competitive moat, contrasting with competitors who may only offer monotherapies.
• Financial Discipline: Reiterated commitment to growing revenue faster than expenses to achieve cash flow break-even, evidenced by year-to-date revenue up 19% while adjusted OpEx declined 2%.

Miscellaneous:

• Cash Position: Ended Q3 2026 with $77.4 million in cash and cash equivalents; cash burn improved 74% YoY to $2.4 million for the quarter.
• Debt: $40 million in debt outstanding; interest-only period extended to August 2027.
• Clinical Evidence: Highlighted robust data from the Sahara RCT regarding Tear Care treating underlying disease vs. symptoms.